Close Menu

NEW YORK (GenomeWeb) – Genomic Health said today that it has signed a multi-year research collaboration agreement with Janssen Pharmaceuticals in which the companies will evaluate Genomic Health's Oncotype DX Genomic Prostate Score as a predictor of response to prostate cancer drugs in Janssen's pipeline.

Under the terms of the agreement, Genomic Health will test samples from studies Janssen is conducting to examine the association of GPS results with clinical outcomes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.